Month: August 2017

Patent Registration Process under Patent Cooperation Treaty (PCT)

With a massive increase in filing of international applications, clients have been constantly asking queries pertaining to patent registration process under Patent Cooperation Treaty (PCT). This article is a quick reference for an overview of procedure for filing an application under PCT route. For filing a patent application in several countries an Applicant can either … Continue reading Patent Registration Process under Patent Cooperation Treaty (PCT)

Read more »

Foreign Filing License Requirement

At various instances, an applicant or an inventor may require to file a patent application directly in a foreign country other than country of residence. There could be diverse reasons pertaining first filing in a foreign country, such as, non-patentable subject matter in country of residence, low market potential in country of residence, etc. In … Continue reading Foreign Filing License Requirement

Read more »

Enzo Biochem Inc. v. Applera Corp. – A case pertaining to Doctrine of Equivalents

On August 02, 2017, the United States Court of Appealsfor the Federal Circuit ruled in favor of Applera Corp.and Tropix Inc.in the matter of Enzo Biochem Inc., Enzo Life Sciences Inc., Yale University v. Applera Corp., Tropix Inc. The Court affirmed that the district court accurately interpreted proper construction of claims in U.S. Patent No.5,449,767 … Continue reading Enzo Biochem Inc. v. Applera Corp. – A case pertaining to Doctrine of Equivalents

Read more »

United States district court upholds the validity of two Horizon Pharma patents covering VIMOVO®

Horizon Pharma plc, an Irish specialty biopharmaceutical company, on 27 June 2017, reported that the United States district court for the district of New Jersey upheld the validity of two Horizon Pharma patents covering VIMOVO®, a pain relief treatment for arthritis patients, and that the ANDA applicants viz. Lupin Limited, Dr. Reddy’s Laboratories and Mylan … Continue reading United States district court upholds the validity of two Horizon Pharma patents covering VIMOVO®

Read more »

TAKEDA PHARMACEUTICAL’S PATENT ON CANCER DRUG VELCADE® UPHELD BY THE US COURT OF APPEALS FOR THE FEDERAL CIRCUIT

On July 17, 2017, the United States Court of Appeals for the Federal Circuit ruled that the U.S. Patent No. 6,713,446 (“the ‘446 patent”) covering Takeda Pharmaceutical’s cancer drug Velcade® is valid and enforceable. The appellate court decision overturned an earlier 2015 decision from a US District Court which ruled the ‘446 patent was invalid … Continue reading TAKEDA PHARMACEUTICAL’S PATENT ON CANCER DRUG VELCADE® UPHELD BY THE US COURT OF APPEALS FOR THE FEDERAL CIRCUIT

Read more »